No Data
Candel Therapeutics, Inc. (NASDAQ:CADL) Most Popular Amongst Individual Investors Who Own 48%, Insiders Hold 30%
Express News | Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to Its Board of Directors
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Candel Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Candel Therapeutics - on Track for Topline Disease-Free Survival Data From Phase 3 Randomized Controlled Clinical Trial of Can-2409
Express News | Candel Therapeutics Inc- Sees Existing Cash & Cash Equivalents Will Be Sufficient to Fund Current Operating Plan Into Q1 2025